Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 12.54
(-2.79%)
SEK 12.54
(-2.79%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 18.22 Million SEK | -27.47% |
| 2022 | 25.13 Million SEK | 43.38% |
| 2021 | 17.52 Million SEK | 95.34% |
| 2020 | 8.97 Million SEK | -18.81% |
| 2019 | 11.05 Million SEK | 66.32% |
| 2018 | 6.64 Million SEK | -14.36% |
| 2017 | 7.75 Million SEK | 97.07% |
| 2016 | 3.93 Million SEK | 137.21% |
| 2015 | 1.65 Million SEK | -12.11% |
| 2014 | 1.88 Million SEK | 697.91% |
| 2013 | 236.68 Thousand SEK | 2068.44% |
| 2012 | 10.91 Thousand SEK | -87.37% |
| 2011 | 86.45 Thousand SEK | -25.85% |
| 2010 | 116.58 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.71 Million SEK | 125.12% |
| 2024 Q1 | 2.53 Million SEK | -52.35% |
| 2023 FY | 18.22 Million SEK | -27.47% |
| 2023 Q2 | 6.29 Million SEK | -22.65% |
| 2023 Q1 | 8.14 Million SEK | 184.92% |
| 2023 Q3 | 12.09 Million SEK | 92.12% |
| 2023 Q4 | 5.32 Million SEK | -55.97% |
| 2022 Q1 | 7.54 Million SEK | 512.2% |
| 2022 FY | 25.13 Million SEK | 43.38% |
| 2022 Q4 | -9.58 Million SEK | -174.91% |
| 2022 Q3 | 12.79 Million SEK | 12.58% |
| 2022 Q2 | 11.36 Million SEK | 50.78% |
| 2021 Q2 | 7.17 Million SEK | -3.9% |
| 2021 FY | 17.52 Million SEK | 95.34% |
| 2021 Q1 | 7.46 Million SEK | 200.28% |
| 2021 Q4 | -1.82 Million SEK | -138.85% |
| 2021 Q3 | 4.7 Million SEK | -34.41% |
| 2020 Q2 | 3.92 Million SEK | -35.17% |
| 2020 Q1 | 6.04 Million SEK | 164.85% |
| 2020 Q3 | 5.53 Million SEK | 41.2% |
| 2020 Q4 | 2.48 Million SEK | -55.06% |
| 2020 FY | 8.97 Million SEK | -18.81% |
| 2019 Q2 | 2.28 Million SEK | 44.97% |
| 2019 Q4 | -9.32 Million SEK | -834.93% |
| 2019 Q3 | 1.26 Million SEK | -44.47% |
| 2019 FY | 11.05 Million SEK | 66.32% |
| 2019 Q1 | 1.57 Million SEK | -14.31% |
| 2018 FY | 6.64 Million SEK | -14.36% |
| 2018 Q4 | 1.83 Million SEK | 3.23% |
| 2018 Q3 | 1.78 Million SEK | 38.32% |
| 2018 Q2 | 1.28 Million SEK | -18.45% |
| 2018 Q1 | 1.57 Million SEK | -79.93% |
| 2017 Q3 | 1.55 Million SEK | 68.85% |
| 2017 FY | 7.75 Million SEK | 97.07% |
| 2017 Q1 | 533.07 Thousand SEK | -38.25% |
| 2017 Q2 | 920.93 Thousand SEK | 72.76% |
| 2017 Q4 | 7.86 Million SEK | 406.06% |
| 2016 Q1 | 804.08 Thousand SEK | 32.0% |
| 2016 FY | 3.93 Million SEK | 137.21% |
| 2016 Q4 | 863.33 Thousand SEK | 16.05% |
| 2016 Q3 | 743.95 Thousand SEK | -48.57% |
| 2016 Q2 | 1.44 Million SEK | 79.91% |
| 2015 Q1 | 445.78 Thousand SEK | -64.36% |
| 2015 FY | 1.65 Million SEK | -12.11% |
| 2015 Q4 | 609.16 Thousand SEK | 177.83% |
| 2015 Q3 | 219.25 Thousand SEK | -7.68% |
| 2015 Q2 | 237.49 Thousand SEK | -46.72% |
| 2014 FY | 1.88 Million SEK | 697.91% |
| 2014 Q3 | 339.72 Thousand SEK | 175.99% |
| 2014 Q2 | 123.09 Thousand SEK | -29.63% |
| 2014 Q4 | 1.25 Million SEK | 268.17% |
| 2014 Q1 | 174.92 Thousand SEK | 0.0% |
| 2013 FY | 236.68 Thousand SEK | 2068.44% |
| 2012 FY | 10.91 Thousand SEK | -87.37% |
| 2011 FY | 86.45 Thousand SEK | -25.85% |
| 2010 FY | 116.58 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 77.998% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 97.021% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 97.021% |
| Arcoma AB | 53.25 Million SEK | 65.769% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -266.846% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.36% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 91.338% |
| CellaVision AB (publ) | 295.99 Million SEK | 93.841% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 73.555% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -1292.361% |
| C-Rad AB (publ) | 3.8 Million SEK | -379.699% |
| Duearity AB (publ) | 21.58 Million SEK | 15.55% |
| Dignitana AB (publ) | 74.73 Million SEK | 75.609% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -575.132% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.831% |
| Iconovo AB (publ) | 63.35 Million SEK | 71.228% |
| Integrum AB (publ) | 90.57 Million SEK | 79.874% |
| Luxbright AB (publ) | 23.09 Million SEK | 21.056% |
| Mentice AB (publ) | 237.06 Million SEK | 92.311% |
| OssDsign AB (publ) | 175.6 Million SEK | 89.619% |
| Paxman AB (publ) | 133.8 Million SEK | 86.376% |
| Promimic AB (publ) | 48.55 Million SEK | 62.456% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 88.774% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 73.95% |
| ScandiDos AB (publ) | 61.03 Million SEK | 70.136% |
| Sectra AB (publ) | 39.06 Million SEK | 53.335% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 89.556% |
| Senzime AB (publ) | 141.51 Million SEK | 87.119% |
| SpectraCure AB (publ) | 12.12 Million SEK | -50.301% |
| Stille AB | 87.21 Million SEK | 79.1% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.673% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 95.866% |